Deal supported by Xplico

By optimeo16|2016-10-19T10:50:32+00:00December, 2015|

Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine.

Deal supported by Xplico

By optimeo16|2016-10-19T10:56:19+00:00November, 2015|

ObsEva and Kissei Pharmaceutical Announce Global Agreement to Develop and Commercialize KLH-2109 for the Treatment of Endometriosis.

Deal supported by Xplico

By optimeo16|2016-10-19T10:53:58+00:00October, 2015|

Nuevolution Announces Drug Discovery Collaboration with Johnson & Johnson Innovation.

Deal supported by Xplico

By optimeo16|2016-10-19T09:40:57+00:00August, 2015|

Inovio Pharmaceuticals enters into Strategic Cancer Vaccine Collaboration and License Agreement with MedImmune

Deal supported by Xplico

By optimeo16|2016-10-19T09:43:48+00:00June, 2015|

LEO Pharma Enters Supply and Distribution Agreement with NeoPharm on Non-Prescription Skin Care Solutions

Deal supported by Xplico

By optimeo16|2016-10-19T09:42:04+00:00April, 2015|

HRA Pharma Closes Investment in Embera NeuroTherapeutics to Advance Development of Novel Therapies for Addiction

Deal supported by Xplico

By optimeo16|2016-10-19T09:45:01+00:00April, 2015|

Medivir and Cancer Research Technology collaborate to develop new class of cancer drugs

Deal supported by Xplico

By optimeo16|2016-10-19T09:45:45+00:00April, 2015|

Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases

Deal supported by Xplico

By optimeo16|2016-10-19T09:48:45+00:00January, 2015|

Curis and Aurigene Announce Collaboration, License and Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets